Prenylation inhibitors: A novel class of antiviral agents

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 6, 2003, Pages 883-886

  Einav, Shirit ^a   Glenn, Jeffrey S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral therapy; Farnesyltransferase inhibitors; Hepatitis delta virus

Indexed keywords

ANTIVIRUS AGENT; BZA 5B; CELL PROTEIN; FTI 2153; INTERFERON; LAMIVUDINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; BONE MARROW SUPPRESSION; CELL FUNCTION; CLINICAL TRIAL; DELTA AGENT HEPATITIS; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL TOXICITY; HEPATITIS DELTA VIRUS; HOST CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIFE CYCLE; LIPID METABOLISM; LIVER TOXICITY; NEUROTOXICITY; NONHUMAN; PRENYLATION; PROTEIN MODIFICATION; PROTEIN PROCESSING; QT PROLONGATION; REVIEW;

ANTIVIRAL AGENTS; HEPATITIS DELTA VIRUS; HUMANS; PROTEIN ISOPRENYLATION; VIRUS ASSEMBLY;

EID: 0346888680     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg490     Document Type: Review

References (31)

1. Zhang, F. L. & Casey, P. J. (1996). Protein prenylation: molecular mechanisms and functional consequences. Annual Review of Biochemistry 65, 241-69.
2. Pereira-Leal, J. B. & Seabra, M. C. (2001). Evolution of the Rab family of small GTP-binding proteins. Journal of Molecular Biology 313, 889-901.
3. Casey, P. J. (1995). Protein lipidation in cell signaling. Science 268, 221-5.
4. Rizzetto, M., Poznetto, A. & Forzani, I. (1991). Epidemiology of hepatitis delta virus: overview. In The Hepatitis Delta Virus (Gerin, J. L., Purcell, R. H. & Rizetto, M., Eds), pp. 1-20. Wiley-Liss, Inc., New York, NY, USA.
5. Alter, M. J. & Hadler, S. C. (1993). Delta hepatitis and infection in north America. In Hepatitis Delta Virus: Molecular Biology, Pathogenesis and Clinical Aspects (Hadziyannis, S. J., Taylor, J. M. & Bonino, F., Eds), pp. 243-50. Wiley-Liss, Inc., New York, NY, USA.
6. Taylor, J. M. (2003). Replication of human hepatitis delta virus: recent developments. Trends in Microbiology 11, 185-90.
7. Gerin, J. L., Casey, J. L. & Purcell, R. H. (2001). Hepatitis delta virus. In Fields Virology (Knipe, D. M. & Howley, P. M., Eds), pp. 3037-50. Lippincott & Wilkins, Philadelphia, PA, USA.
8. Chao, M., Hsieh, S. Y. & Taylor, J. (1990). Role of two forms of hepatitis delta virus antigen: evidence for a mechanism of self-limiting genome replication. Journal of Virology 64, 5066-9.
9. Glenn, J. S. & White, J. M. (1991). Trans-dominant inhibition of human hepatitis delta virus genome replication. Journal of Virology 65, 2357-61.
10. Wei, Y. & Ganem, D. (1998). Activation of heterologous gene expression by the large isoform of hepatitis delta antigen. Journal of Virology 72, 2089-96.
11. Chang, F. L., Chen, P. J., Tu, S. J. et al. (1991). The large form of hepatitis delta antigen is crucial for assembly of hepatitis delta virus. Proceedings of the National Academy of Sciences, USA 88, 8490-4.
12. Glenn, J. S., Watson, J. A., Havel, C. M. et al. (1992). Identification of a prenylation site in delta virus large antigen. Science 256, 1331-3.
13. Hwang, S. B, Lee, C. Z. & Lai, M. M. C. (1992). Hepatitis delta antigen expressed by recombinant baculoviruses: comparison of biochemical properties and post-translational modifications between the large and small forms. Virology 190, 413-22.
14. Otto, J. C. & Casey P. J. (1996). The hepatitis delta virus larege antigen is farnesylated both in vitro and in animal cells. Journal of Biological Chemistry 271, 4569-72.
15. Glenn, J. S., Marsters, J. C. & Greenberg, H. B. (1998). Use of a prenylation inhibitor as a novel antiviral agent. Journal of Virology 72, 9303-6.
16. James, G. L., Brown, M. S., Cobb, M. H. et al. (1994). Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras-transformed cells, but not in untransformed cells. Journal of Biological Chemistry 269, 27705-14.
17. Bordier, B. B., Marion, P. L., Ohashi, K. et al. (2002). A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. Journal of Virology 76, 10465-72.
18. Sureau, C., Moriarty, A. M., Thornton, G. B. et al. (1992). Production of infectious hepatitis delta virus in vitro and neutralization with antibodies directed against hepatitis B virus pre-S antigens. Journal of Virology 66, 1241-5.
19. Casey, J. L., Brown, T. L., Colan, E. J. et al. (1993). A genotype of hepatitis D virus that occurs in northern South America. Proceedings of the National Academy of Sciences, USA 90, 9016-20.
20. Bordier, B. B., Okhanda, J., Lee, S. Y. et al. (2003). In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. Journal of Clinical Investigation 112, 407-14.
21. Dienstag, J. L., Schiff, E. R., Wright, T. L., et al. (1999). Lamivudine as initial treatment for chronic hepatitis B in the United States. New England Journal of Medicine 341, 1256-63.
22. Lau, D. T., Doo, E., Park, Y. et al. (11999). Lamivudine for chronic delta hepatitis. Hepatology 30, 546-9.
23. Wolters, L. M., van Nunen, A. B., Honkoop, P. et al. (2000). Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. Journal of Viral Hepatitis 7, 428-34.
24. Sebti, S. M. & Hamilton, A. D. (2000). Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 19, 6584-93.
25. ras but does not affect their function or localization. Cancer Research 55, 3295-304.
26. Sharma, S., Kemeny, N., Kelsen, D. P. et al. (2002). A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Annals of Oncology 13, 1067-71.
27. Farnsworth, C. C., Gelb, M. H. & Glomset J.A. (1990). Identification of geranylgeranyl-modified proteins in HeLa cells. Science 247, 320-2.
28. McGeoch, D. J., Dalrymple, M. A., Davison, A. J. et al. (1988). The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. Journal of General Virology 69, 1531-74.
29. Farassati, F., Yang, A. D. & Lee, P. W. K. (2001). Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nature Cell Biology 3, 745-50.
30. Glenn, J. S. (1999). Prenylation and virion morphogenesis. In The Unique Hepatitis Delta Virus (Gottlieb, G. D., Ed.), pp. 83-93. RC Landes Publishing Co., Austin, TX, USA.
31. Sinensky, M., Beck, L. A., Leonard, S. et al. (1990). Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. Journal of Biological Chemistry 265, 19937-41.